Kinex Pharmaceuticals and Hanmi Pharmaceutical Announce First Patient has been Enrolled in Phase 1b/IIa Clinical Trial in Korea

Kinex Pharmaceuticals and Hanmi Pharmaceutical Announce First Patient has been
               Enrolled in Phase 1b/IIa Clinical Trial in Korea

PR Newswire

BUFFALO, N.Y., Jan. 7, 2013

BUFFALO, N.Y., Jan. 7, 2013 /PRNewswire/ -- Kinex Pharmaceuticals and Hanmi
Pharmaceutical announced today that the first patient has been enrolled in
Hanmi's Phase Ib / IIa clinical trial in Korea. Kinex's dual Src/pretubulin
Inhibitor, KX01, is being combined with intravenous (IV) paclitaxel to treat
solid tumor patients in Phase Ib and then gastric and breast cancer patients
in Phase IIa.

KX01 (KX2-391) is an once daily, orally administered potent small molecule Src
kinase/pretubulin dual mechanism inhibitor discovered by Kinex Pharmaceuticals
using its proprietary technology platforms Mimetica™^and Opal™. KX01
differentiates itself as a non-ATP competitive Src signaling inhibitor and,
therefore, offers excellent efficacy as well as safety profile. KX01 has been
shown to be very effective against a broad range of cancers in both in vitro
experiments and in animal cancer models. Importantly, the compound has
synergistic activities with most taxanes, including paclitaxel which is
combined with KX01 in the current Phase Ia / IIb trial. A completed Phase I
study, in patients with end-stage cancer and twice daily dosing, showed a
desirable safety profile and clinical stable diseases in approximately 25% of
the patients. An ongoing KX01 AML mono-therapy Phase I trial has shown that
once daily dosing allows much higher KX01 blood levels to be achieved while
still maintaining and excellent safety profile. The composition of matter,
use and synthesis/formulation of KX01 is covered by issued and pending patents
globally.

David Hangauer, CSO of Kinex, commented, "We are delighted that the Hanmi team
continues to be excellent partners for the development of KX01. We are very
excited that they have initiated the KX01 / paclitaxel trial. KX01 has shown
strong synergy in vitro and in vivo with paclitaxel and it will be an
important advancement in cancer therapy if such synergy is also present in
actual clinical setting."

"Hanmi filed their Korean IND in the 3Q of 2012, it was approved in the 4Q of
2012, and they have now enrolled their first patient. Their commitment to the
KX01 program is extraordinary," said Dr. Rudolf Kwan, CMO of Kinex. "I have
visited the Korean clinical sites and am extremely pleased with the very high
clinical research standard set by our partner, Hanmi. The KX01 program is
important in its own right, but it also allows us to further refine our
strategy of combining KX01 with Oraxol, an oral paclitaxel product discovered
by Hanmi that is currently being developed through a joint development program
between Kinex and Hanmi."

Dr. Jeewoong Son, Senior VP and Head of Innovation at Hanmi added, "The Hanmi
and Kinex teams worked together very diligently to submit our Korean IND in a
timely manner. We are pleased to see Kinex's strong commitment to
aggressively move forward with KX01 and the Orascovery program. We hope that
our joint effort will lead to an oral treatment that provides an important new
option for many cancer patients."

About Kinex Pharmaceuticals

Kinex Pharmaceuticals, headquartered in Buffalo, New York, USA, is using its
proprietary technologies Mimetica and Opal to discover and develop novel drugs
for oncology and immune-modulatory diseases. More information of Kinex
Pharmaceuticals can be found at www.kinexpharma.com

About Hanmi Pharmaceutical, Co., Ltd

Established in 1973 in Korea, Hanmi Pharmaceuticals now is one of the top 5
pharmaceutical companies in terms of revenue, and the most R&D focused company
with the highest R&D investment for several years. Hanmi has been successful
for a few decades with high flexibility, continuously changing its
market/development strategy from first generics to IMD & FDC (Incrementally
Modified Drug and Fixed Dose Combination) to new drug development including
innovative small molecules and biologics. During the period of significant
changes, Hanmi made multiple strategic collaboration relationships with
multinational companies and biotech companies.

For further information about Hanmi Pharmaceuticals, please refer to
www.hanmipharm.com

Kinex Inquiries:

Patrick Gallagher
Vice President, Business Development and Investor Relations
Kinex Pharmaceuticals
701 Ellicott Street
Buffalo, NY 14203
pgallagher@kinexpharma.com

SOURCE Kinex Pharmaceuticals

Website: http://www.kinexpharma.com
 
Press spacebar to pause and continue. Press esc to stop.